Potomac Capital Management Inc. Buys Shares of 141,172 Evolus, Inc. $EOLS

Potomac Capital Management Inc. bought a new stake in Evolus, Inc. (NASDAQ:EOLS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 141,172 shares of the company’s stock, valued at approximately $939,000.

Other large investors also recently bought and sold shares of the company. Divisadero Street Capital Management LP acquired a new position in Evolus in the third quarter valued at about $2,384,000. HighVista Strategies LLC lifted its position in Evolus by 289.4% in the third quarter. HighVista Strategies LLC now owns 226,025 shares of the company’s stock valued at $1,388,000 after buying an additional 167,983 shares during the last quarter. Pinnacle Associates Ltd. lifted its position in Evolus by 15.9% in the fourth quarter. Pinnacle Associates Ltd. now owns 782,365 shares of the company’s stock valued at $5,203,000 after buying an additional 107,490 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Evolus in the third quarter valued at about $167,000. Finally, Profund Advisors LLC lifted its position in Evolus by 67.3% in the third quarter. Profund Advisors LLC now owns 18,121 shares of the company’s stock valued at $111,000 after buying an additional 7,288 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Stock Performance

Shares of EOLS opened at $6.70 on Wednesday. The stock has a market capitalization of $441.26 million, a PE ratio of -10.00 and a beta of 1.34. Evolus, Inc. has a 1 year low of $3.86 and a 1 year high of $10.62. The company’s 50-day simple moving average is $5.56 and its 200-day simple moving average is $5.56.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million. During the same quarter in the previous year, the company earned ($0.30) earnings per share. On average, sell-side analysts predict that Evolus, Inc. will post -0.38 earnings per share for the current year.

Insider Activity

In other news, insider Rui Avelar sold 29,996 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the sale, the insider owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Moatazedi sold 13,669 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $64,927.75. Following the sale, the insider directly owned 604,700 shares in the company, valued at $2,872,325. This represents a 2.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 163,504 shares of company stock worth $797,184 in the last three months. Corporate insiders own 5.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on EOLS shares. Weiss Ratings cut shares of Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $13.00 target price on shares of Evolus in a research report on Wednesday, March 4th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.